Analyst Ratings For Abbott Laboratories (NYSE:ABT)
Today, JPMorgan Chase & Co. raised its price target on Abbott Laboratories (NYSE:ABT) to $81.00 per share.
There are 14 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $72.5294 per share, a potential 2.37% upside.
Some recent analyst ratings include
- 7/19/2018-Abbott Laboratories (NYSE:ABT) had its Buy rating reiterated by Royal Bank of Canada with a $70.00 price target
- 6/27/2018-Abbott Laboratories (NYSE:ABT) has coverage initiated with a Outperform rating and $73.00 price target
Recent Insider Trading Activity For Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE:ABT) has insider ownership of 0.74% and institutional ownership of 72.16%.
- On 9/28/2018 Daniel Gesua Sive Salvadori, Insider, sold 5,000 with an average share price of $73.39 per share and the total transaction amounting to $366,950.00.
- On 9/28/2018 Sharon J Bracken, SVP, sold 1,732 with an average share price of $73.35 per share and the total transaction amounting to $127,042.20.
- On 9/20/2018 Brian J Blaser, Insider, sold 58,200 with an average share price of $68.79 per share and the total transaction amounting to $4,003,578.00.
- On 8/29/2018 Andrew H Lane, Insider, sold 9,097 with an average share price of $67.11 per share and the total transaction amounting to $610,499.67.
- On 8/29/2018 Jaime Contreras, SVP, sold 64,268 with an average share price of $66.84 per share and the total transaction amounting to $4,295,673.12.
- On 7/30/2018 Sharon J Bracken, Insider, sold 615 with an average share price of $65.16 per share and the total transaction amounting to $40,073.40.
- On 7/24/2018 Brian J Blaser, EVP, sold 15,100 with an average share price of $63.96 per share and the total transaction amounting to $965,796.00.
About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 70,92 −0,66 0,92 % with 70.78 shares trading hands.